Abstract:AIM:Point mutation, one of the commonest gene mutations, is the most important molecular pathogenesis of cancer and chronic infection. The commonest methods for detection of point mutation are based on polymerase chain reaction (PCR). These techniques, however, cannot be used in large scale screening since they are neither accurate nor simple. For this reason, this study established a novel method of competitively differentiated PCR (CD-PCR) for screening point mutation in clinical practice.METHODS:Two competitively differentiated primers for mutant-type and wild-type templates respectively with an identically complemented region in 3' end except for last 2 base pairs and a different non-complemented region in 5' end were designed. Thus, competitive amplification might be carried out at a lower annealing temperature at first, and then differentiated amplification at a higher annealing temperature when primers could not combine with initial templates. The amplification was performed in one-tube. The products of CD-PCR were detected using microplate hybridization assay. CD-PCR was evaluated by detecting G1896A variant of hepatitis B virus (HBV) in form of recombinant plasmids and in sera from patients with hepatitis B, and compared with allele-specific PCR (AS-PCR) and competitive AS-PCR.RESULTS:CD-PCR was successfully established. It could clearly distinguish wild-type and mutant-type plasmid DNA of G1896A variant when the amount of plasmid DNA was between 10(2)-10(8)copies/reaction, while for AS-PCR and competitive AS-PCR, the DNA amount was between 10(2)-10(4)copies/reaction. CD-PCR could detect one copy of G1896A variant among 10-100 copies of wild-type plasmid DNA. The specificity of CD-PCR was higher than those of AS-PCR and competitive AS-PCR in the detection of HBV G1896A variant in sera from patients with hepatitis B. CD-PCR was independent of the amount of HBV DNA in serum. HBV G1896A variant was more often found in HBeAg (-) patients with a lower level of detectable viremia than that with a higher level of detectable viremia (P=0.0192).CONCLUSION:CD-PCR is more specific since it is less influenced by the amount of initial templates and the cross amplification between mutant- and wild-type amplified products. It is also simple and time-saving. Thus, CD-PCR might be useful in routine gene typing and point mutation screening. HBV G1896A or other more important mutations have to be routinely detected in patients with a detectable level of viremia after HBeAg/antibody conversion in clinical practice.

A Novel Method Based on Ligase Detection Reaction for Low Abundant YIDD Mutants Detection in Hepatitis B Virus

Detection of Hepatitis B Virus Large Surface Protein Using a Time‐Resolved Immunofluorometric Assay

Rapid and High Throughput Detection of Hbvymdd Mutants with Fluorescence Polarization

Detection and RFLP Analysis of the Polymerase Gene Mutation of HBV DNA

Detecting of the Hepatic Fibrotic Indexes and Serous Markers from Patients with Chronic Hepatitis B (chb)and Variation of HBV DNA YMDD

YMDD Variants of HBV DNA Polymerase Gene: Rapid Detection and Clinicopathological Analysis with Long-Term Lamivudine Therapy after Liver Transplantation.

Multiplex Locked Nucleic Acid Probes for Analysis of Hepatitis B Virus Mutants Using Real-Time PCR

A Novel Phenotypic Assay of Hepatitis B Virus Polymerase with Extensive Site-Specific Mutagenesis

P.038 Differences of Ymdd Mutational Patterns, Pre-Core/core Promoter Mutations, Serum Viral Loads in Lamivudine-Resistant Hepatitis B Genotypes B and C

Application of PCR‐LDR‐nucleic Acid Detection Strip in Detection of YMDD Mutation in Hepatitis B Patients Treated with Lamivudine

Detection and Analysis of Gene Mutation of HBV DNA

Reverse Line Probe Hybridization Assay for Detection of Lamivudine-Resistant Chronic Hepatitis B Virus

[Study of gene chips in the detection of YMDD mutations in the region of HBV polymeras]

Rapid Identification of YVDD Mutants of Hepatitis B Virus Using Smart Amplification Process with Competition Probe.

Analysis of YMDD Mutants in Hepatitis B Virus Infected Patients with Lamivudine Therapy by Restriction Fragment Length Polymorphism (RFLP) of the PCR Products

Novel Assay of Competitively Differentiated Polymerase Chain Reaction for Screening Point Mutation of Hepatitis B Virus.

Monitoring of the Emergence of Hepatitis B Virus YMDD Variants by Fluorometric Real-Time PCR

A Nanoscale Mutation-Sensitive On/Off Switch Based Assays for the Detection of Hepatitis B Virus Lamivudine-Resistant Mutations

Simultaneous Detection of Two Major Lamivudine-Resistant Mutants Using Competitively Differentiated-Pcr.

Application of PCR-RFLP in detection of adefovir dipivoxil resistance-associated mutations in hepatitis B virus

To establish a new and simple method of genotyping of hepatitis B virus by PCR-RFLP to analysis on S region